HIV Immunogens: Affinity Is Key

Savit Prabhu; Ian A Cockburn; Carola G Vinuesa

doi:10.1016/j.immuni.2018.01.002

HIV Immunogens: Affinity Is Key

Immunity. 2018 Jan 16;48(1):11-13. doi: 10.1016/j.immuni.2018.01.002.

Authors

Savit Prabhu¹, Ian A Cockburn¹, Carola G Vinuesa²

Affiliations

¹ Department of Immunology and Infectious Disease, The John Curtin School of Medical Research, Australian National University, Canberra, Australia.
² Department of Immunology and Infectious Disease, The John Curtin School of Medical Research, Australian National University, Canberra, Australia. Electronic address: carola.vinuesa@anu.edu.au.

PMID: 29343432
DOI: 10.1016/j.immuni.2018.01.002

Abstract

Generation of broadly neutralizing antibodies is a key aim of HIV vaccine design, but the precursor B cells are rare. Abbott et al. (2018) report that high affinity and avidity immunogens are required to promote maturation of low frequency B cells in germinal centers.

Publication types

Comment

MeSH terms

AIDS Vaccines
Antibodies, Neutralizing
HIV Antibodies*
HIV Infections
HIV-1 / immunology*
Humans

Substances

AIDS Vaccines
Antibodies, Neutralizing
HIV Antibodies